• UK medicines regulator MHRA cleared a Phase 1/2 trial of Moderna’s investigational mRNA cancer vaccine mRNA-4194 for people with Lynch syndrome.
• The study is sponsored by the University of Oxford, with Moderna funding, to assess safety, immune response, and dose.
• First patient dosing is expected this summer; a multi-center UK expansion phase is slated to start in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606081901ACCESSWRNAPR_____1174103) on June 08, 2026, and is solely responsible for the information contained therein.